Hennigsdorf, May 3, 2024

As of today, Ansgar Santel acts as the new Chief Executive Officer and becomes an additional member of the Board of Managing Directors at Pantherna Therapeutics GmbH with Jörg Kaufmann and Gerrit Maass. Ansgar joined Pantherna in November 2021 as Head of Translational Research and Alliance Management. He has a wealth of experience in developing new innovative RNA therapies whilst exhibiting exceptional leadership qualities. We at Pantherna are proud to welcome Ansgar into his new role as CEO and are confident in his commitment to accelerating Pantherna’s innovation and success in the development of impactful RNA therapies.

Der Beitrag Company update: Ansgar Santel appointed as new CEO erschien zuerst auf Pantherna Therapeutics.

Pantherna Therapeutics announces grant of Key European Patent for its advanced mRNA expression technology.
Hennigsdorf, December 27, 2023

Pantherna Therapeutics, a privately held biotechnology company developing first-in-class therapeutics based on its proprietary mRNA-LNP technologies, today announced that European patent EP3833786B has been issued by the European Patent Office (EPO), securing an innovative, universally applicable mRNA expression cassette for enhanced translation of proteins aiming at restoring cellular function in the context of mRNA therapies.
“The decision of the EPO marks an important step for Pantherna in building a comprehensive patent portfolio to protect its mRNA-based platform technology and drug candidates”, said Dr. Klaus Giese, CEO of Pantherna Therapeutics.

Der Beitrag Press release grant of EP patent erschien zuerst auf Pantherna Therapeutics.

We are delighted to announce and share the acceptance of our new peer-reviewed publication in “Molecular Therapy – Nucleic Acids” highlighting our research findings and charactersation of our cLNP002 mRNA-formulation for spatial expression of a Tie2-agonist in the vascular endothelium of the lung.

These findings build the basis for our motivation and vision to translate this concept into clinical practice.
Have a look at our paper and spread the news!

Der Beitrag New article alert: “Cationic LNP-formulated mRNA expressing Tie2-agonist in the lung endothelium prevents pulmonary vascular leakage”. erschien zuerst auf Pantherna Therapeutics.

In this month’s issue of Drug Development & Delivery our research team Charlotte Dunne, PhD, Katrin Radloff, PhD and Leonidas Gkionis, PhD describe Pantherna’s mRNA and LNP technology platforms.
Pantherna has established the “3-flavour” PTXΔLNP platform for mRNA formulation with precision fine tuning to produce cell-selective LNPs in addition to high batch-to-batch consistency, robust stability, and improved delivery efficiency.

Read more here to learn about local and systemic therapeutic opportunities for the PTXΔLNP® Platform in combination with Pantherna’s sister technology platform PTXmRNA®.

Der Beitrag New article alert: “The PTXΔLNP® Platform: On the Promise of Developing New LNPs for Tomorrow’s mRNA Therapies”. erschien zuerst auf Pantherna Therapeutics.

Pantherna Therapeutics GmbH, a privately held German biotech company, developing new mRNA therapies, collaborates with UMR to research the therapeutic potential of its PTX-mRNA-LNP platform technologies in treating eye diseases connected to corneal endothelial dysfunction.  

Der Beitrag Pantherna Therapeutics teams up with University Medicine Rostock (UMR) on exploring new opportunities for mRNA therapy in ocular disease erschien zuerst auf Pantherna Therapeutics.

The preclinical data demonstrate that tumor neoantigens identified by Evaxion’s AI platform, PIONEER, drive a strong immune response and lead to complete inhibition of tumor growth in a preclinical model when delivered using Pantherna’s proprietary lipid nanoparticle mRNA platform (PTXΔLNP®, PTXmRNA®).

“We are extremely pleased with the preclinical data that clearly demonstrate the potential for our combined technologies. The data provide further evidence that immunogenic sequences identified by Evaxion’s AI platforms are able to drive a relevant immune response on multiple vaccine platforms, including mRNA. This opens up many opportunities in our current and future immuno-oncology and infectious disease programs,” says Birgitte Rønø, CSO at Evaxion.

“We are encouraged by the data and see an enormous potential of combining Evaxion’s AI-based antigen discovery engines with our state-of-the-art mRNA-LNP platforms. The preclinical data substantiate the relevance of enhancing the efficiency of mRNA actions in the body and validates the ability of our platform to induce an immune response,” says Klaus Giese, CEO at Pantherna.

In continuation of these positive findings, Evaxion and Pantherna will further explore optimal LNP formulations to effectively deliver mRNA and DNA-encoded antigens identified by Evaxion’s AI platforms.

 About Evaxion

Evaxion Biotech A/S is a clinical-stage biotech company developing AI-powered immunotherapies. Evaxion’s proprietary and scalable AI technologies decode the human immune system to discover and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has a broad pipeline of novel product candidates, including three personalized cancer immunotherapies. It is located in Hørsholm, Denmark, with 70 employees and is listed on the Nasdaq New York stock exchange. For more information, please visit: www.evaxion-biotech.com.

 About Pantherna

Pantherna Therapeutics is a privately held biopharmaceutical company developing first-in-class mRNA therapeutics. Pantherna’s innovative technology platform is based on advanced lipid nanoparticles for the target-specific, selective delivery and expression of therapeutic mRNA drugs in organs and tissues such as the vascular endothelium. Pantherna is based in Hennigsdorf, Brandenburg (Innovationsforum) close to Berlin, Germany. For more information, please visit https://pantherna-therapeutics.com/.

For more information, please contact:

Katrine Hertz Mortensen
VP, Communications and Public Relations
khm@evaxion-biotech.com
+45 3010 0203

Gerrit Maass
CFO
g.maass@pantherna-therapeutics.com
+49 3302-202 240-0

Der Beitrag Evaxion and Pantherna announce promising preclinical mRNA vaccine data erschien zuerst auf Pantherna Therapeutics.

This agreement expands the scope of the technology evaluation agreement for research, which Astellas and Pantherna entered into in 2021, to include new target organ.

Pantherna owns a proprietary platform of state-of-the-art, unique mRNA molecules (PTXmRNAs) for enhancing the efficiency of mRNA actions in the body. Under the new agreement, Pantherna’s mRNA platform and Astellas’ world-class drug discovery capabilities will be combined to promote research on the generation of regenerative medicine programs for new target organ using a direct reprogramming approach. Astellas will be responsible for providing drug discovery ideas, preparing candidate compounds for technology evaluation, and performing research aimed at developing this therapeutic modality, while Pantherna will be responsible for  providing technical information and development support.

“We are excited about this expansion of our collaboration with Astellas,” said Pantherna’s Chief Executive Officer, Klaus Giese, Ph.D. “We feel honored that Astellas, as a leading pharmaceutical company, has underscored their interest in leveraging the unique aspects of our proprietary therapeutic mRNA technology.”

“Through this agreement, which expands the scope of our collaboration with Pantherna, we will create innovative regenerative medicine programs for new target organ, and we expect that we will be able to thereby expand the treatment options for diseases with high unmet medical needs.” said Taiji Sawamoto, Ph.D., Executive Vice President, Applied Research & Operations, at Astellas. “The collaboration with Pantherna is an initiative which synergistically integrates Astellas’ expertise with mRNA as a therapeutic modality and its capabilities cultivated in the research field of direct reprogramming, and will promote the development of next-generation treatments using a new modality/technology based on the Focus Area approach strategy.”

* Direct reprogramming: Direct conversion of the fate of cells without passing through the pluripotent state. https://www.astellas.com/en/science/direct-reprogramming-research-unit

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+^® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.

About Pantherna

Pantherna Therapeutics is a privately held biopharmaceutical company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced lipid nanoparticles for the target-specific, selective delivery and expression of therapeutic mRNA drugs in organs and tissues such as the endothelium. Pantherna Therapeutics was recently awarded with a 2022 Pharma Trend Honor for its lead candidate PAN004 in the category “Most Innovative Product: Leap Innovations-Nucleic Acid-Based Drug Development”

(https://businesswire.com/news/home/20220916005215/en/Pharma-Trend-Honors-the-Best-Pharmaceutical-Companies-and-the-Most-Innovative-Products_2022). Pantherna is based in Hennigsdorf, Brandenburg (Innovationsforum) close to Berlin, Germany. For more information, please visit our website at https://pantherna-therapeutics.com/.

Cautionary Notes (Astellas)

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Advocacy & Relations
TEL: +81-3-3244-3201

Pantherna Therapeutics GmbH

Dr. Gerrit Maass

CFO

TEL:  +49(0)3302-202 240-0

E-Mail:  g.maass@pantherna-therapeutics.com

Der Beitrag Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming erschien zuerst auf Pantherna Therapeutics.

Pantherna, a privately-held German biotech company, developing new mRNA therapies, today announced a research collaboration with Charité – Universitätsmedizin Berlin, exploring the potential of mRNA therapies in treating autoimmune diseases. Together with clinician scientists from the Charité Department of Clinical Neuroimmunology Pantherna aims to investigate the potential of its PTX-mRNA and PTX-LNP technologies as a therapeutic means to fight autoimmune diseases.  Neurological conditions such as Neuromyelitis optica spectrum disorders (NMOSD) are caused by auto-antibodies attacking endogenous proteins and consequently destroying essential cells such as astrocytes or oligodendrocytes. Despite immunosuppressive amelioration of the symptoms no specific treatment exists for this rare debilitating chronic disease. Prof. Friedemann Paul and Dr. Maria Hastermann and their team at Charité unravel the pathological basis for autoimmunity in NMOSD and strive to find novel therapeutic modalities. Both parties agreed on the conduct of preclinical studies, addressing the suitability of novel LNP-compositions to control tolerogenic immune responses.

Contact for additional information:

Pantherna Therapeutics GmbH

Dr. Ansgar Santel, Head of Translational Research and Alliance Management
T: +49(0)3302-202 240-0
E-Mail: a.santel@pantherna-therapeutics.com

Der Beitrag Pantherna Therapeutics collaborates with Charité – Universitätsmedizin Berlin to investigate the potential of therapeutic mRNA in autoimmune disease erschien zuerst auf Pantherna Therapeutics.

Der Beitrag Astellas and Pantherna Enter into Technology Evaluation Agreement for Research of mRNA-based Regenerative Medicine. erschien zuerst auf Pantherna Therapeutics.

Der Beitrag Pantherna Therapeutics to be granted 2.2 millions EFRE public funding. erschien zuerst auf Pantherna Therapeutics.